Multiple myeloma

Active Ingredient: Motixafortide

Indication for Motixafortide

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Motixafortide is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

For this indication, competent medicine agencies globally authorize below treatments:

1.25 mg/kg via slow subcutaneous injection 10 to 14 hours prior to the initiation of the first apheresis

For:

Dosage regimens

Subcutaneous, 1.25 milligrams motixafortide per kilogram of body weight, one dose.

Detailed description

Important dosing information

  • Premedicate all patients before each dose of motixafortide to reduce the risk of hypersensitivity and injection site reactions:
    • Administer diphenhydramine (12.5 mg intravenously or 25 mg to 50 mg orally, or another H1-antihistamine), an H2 blocker (e.g., famotidine), and a leukotriene inhibitor (e.g., montelukast) approximately 30 to 60 minutes before injection of motixafortide.
  • The addition of an analgesic medication (e.g., acetaminophen) to the premedication regimen is recommended.
  • Administer filgrastim 10 mcg/kg subcutaneously once daily for 4 days prior to the first dose of motixafortide and on each day prior to each apheresis.

Recommended dosage

The recommended dosage of motixafortide is 1.25 mg/kg administered via slow (approximately 2 minutes) subcutaneous injection 10 to 14 hours prior to the initiation of the first apheresis. Dosing is based on actual body weight.

A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary.

Dosage considerations

  • Administer injection into the abdomen, the back or side of the upper arms, or the thighs. Rotate injection sites. An injection should never be given into scar tissue or areas that are reddened, inflamed, or swollen. If injecting into the abdomen, avoid a 5 cm diameter circle around the navel. If more than one injection is needed for a single dose of motixafortide, the injection sites should be at least 2 cm apart from previous injection locations. Discard unused portion of the drug.
  • Monitor patients for one hour after administration.

Active ingredient

Motixafortide

Motixafortide is an inhibitor of the C-X-C Motif Chemokine Receptor 4 (CXCR4) and blocks the binding of its cognate ligand, stromal-derived factor-1α (SDF-1α)/C-X-C Motif Chemokine Ligand 12 (CXCL12). SDF-1α and CXCR4 play a role in the trafficking and homing on human hematopoietic stem cells to the marrow compartment.

Read more about Motixafortide

Related medicines

Structured Product Labeling (SPL/PLR) 2023: APHEXDA Powder for solution for injection

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.

⇈